Home › GLP-1 eligibility UK
Who can be prescribed GLP-1 weight-loss treatment in the UK
About this page. Written by the GLPInfo editorial team with AI assistance from the official sources listed at the end, and approved by the site owner before publication. It has not been reviewed by a named clinician. Published 27 Aug 2026 · last updated 27 Aug 2026 · next scheduled review 27 Nov 2026.
This page is information, not medical advice. It never tells you which medicine, dose or format is right for you: those decisions sit with you and a qualified prescriber. Spotted an error? Tell us and we'll fix it fast.
All four licensed treatments share the same core eligibility frame, set by their licences and applied by prescribers. This page states the criteria as licensed, explains how online providers verify them, and is deliberately not a checklist for talking your way in: the criteria protect you.
The licensed criteria
Mounjaro, Wegovy (injection and tablet) and Foundayo are all licensed for weight management in adults with a BMI of 30 or above, or 27 and above with at least one weight-related condition, in each case alongside a reduced-calorie diet and increased physical activity. Wegovy additionally has an adolescent licence used only under specialist care. BMI thresholds are the entry frame, not the whole assessment: the prescriber also weighs your medical history, current medicines, pregnancy and breastfeeding status, and the contraindications in each medicine's leaflet.
How verification works at UK online providers
The questionnaire alone is no longer the norm. Regulated providers increasingly require a full-body photo or a video call, and may ask for ID, before a prescriber reviews the application. Providers apply their own clinical thresholds on top of the licence, so practice varies; what does not vary is that the decision belongs to their prescriber. If a provider appears willing to prescribe with no meaningful checks, treat that as a warning sign and run the checks in how to check a UK weight-loss provider.
Honesty in the assessment protects you
These are potent medicines with real contraindications. Overstating weight, omitting medicines, or borrowing someone else's photos does not beat the system; it removes the safety layer the system exists to provide, and the person it endangers is you. If you are not eligible now, the NHS page on obesity covers the routes that do apply, and your GP can advise on NHS weight-management services.
What it costs if you are eligible
Eligibility and affordability are separate questions. Our comparisons show what each treatment costs at every dose from every provider we list, re-checked every 12 hours: Mounjaro, Wegovy, Wegovy pill, Foundayo, and the true cost guide shows what a realistic multi-month course adds up to.
Frequently asked questions
What BMI do you need for GLP-1 weight-loss treatment in the UK?
The licences for Mounjaro, Wegovy (injection and pill) and Foundayo all cover adults with a BMI of 30 or above, or 27 and above with at least one weight-related condition such as type 2 diabetes, high blood pressure or sleep apnoea, always alongside a reduced-calorie diet and increased physical activity. The prescriber applies these criteria; a comparison site cannot tell you whether you qualify.
How do online providers check my BMI is real?
Regulated UK providers now commonly require photo or video verification alongside the questionnaire, and some request ID or a weight check on video. This is a good sign, not an obstacle: a provider that would prescribe without verifying is a provider to avoid. How to check a provider.
Why was I declined?
Providers decline when the licensed criteria are not met, when a health condition or medicine in your history makes GLP-1 treatment unsuitable, or when verification does not match the questionnaire. A decline from one regulated provider for clinical reasons is likely to repeat elsewhere, and shopping around for a yes is a risk to your health, not a workaround.
Can I get these medicines on the NHS?
Tirzepatide is being rolled out in phases in primary care under NICE guidance prioritising highest clinical need; semaglutide is available through some specialist services; Foundayo is private-only at launch. Criteria and availability change: check the NHS website or your GP.